EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer 1) If remission, initiate targeted therapy w/out delay 2) Prefer anti-cytokine bDMARDs if Hx solid cancer 3) B cell depleting therapy if Hx lymphoma 4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1

#EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/bBtBm1olcr

Belimumab in Lupus Nephritis Belimumab is a BLyS-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis. https://t.co/f2odJWlyR2 https://t.co/y5exJIFzht

Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG

Prediction of RA early arthritis & clinically suspect arthralgia pts w/ AI analysis of MRIs scans: ✔️Feasible ✔️Accurate AUC 0.683 EA group AUC 0.727 CSA group ✔️Peformance = human experts ✚ Could identify new imaging biomarkers https://t.co/sVXw9A8NqZ OP0002 #EULAR23 @Rheumnow https://t.co/oq5RJApm9U

Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs HR ILD RA=10 HR ILD PsA=5 No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication? https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs

Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

https://t.co/0FsCCOP17E OP0044 #EULAR23 @RheumNow https://t.co/pl0AnGUAw1

Scandinavian RA registry study shows reassuring data on CV risk in RA🫀 Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi. https://t.co/wBDZtaTVba OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF

Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure Here’s the ILD risk for methotrexate. Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC